tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

ANI Pharmaceuticals sees FY23 EPS, revenue ‘within or above guidance ranges’

For full year 2025, total net revenues, adjusted non-GAAP EBITDA, and adjusted non-GAAP diluted EPS expected to be within or above guidance ranges of $854M-$873M, $221M-$228M and $7.37-$7.64, respectively. FY25 EPS/revenue consensus $7.52/$868.67M, respectively.

Claim 70% Off TipRanks Premium

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1